Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Roche's second China-to-West ALK7 siRNA deal with Rona follows Arrowhead's Phase 1 data showing adipose-tissue knockdown. Stephen Hansen says ALK7 is not a liver target, so companies must solve delivery to fat tissue; Simone Fishburne says RNAi's clinical validation lets China biotechs take biology risk.

Related Insights

The biggest obstacle holding back the entire RNA field, including mRNA and oligonucleotides, is the challenge of delivering these therapies beyond the liver. A breakthrough in novel delivery mechanisms is considered more critical for unlocking the modality's therapeutic potential than discovering new RNA molecules.

After decades of work, small interfering RNA (siRNA) has overcome delivery challenges to become a mature, "de-risked" platform, primarily for liver-directed targets. This now enables powerful medicines like a once-yearly injection for high cholesterol, representing a major public health breakthrough.

While GLP-1s dominated the obesity narrative, the next wave of innovation is focused on novel mechanisms. Arrowhead's significant fundraise for its siRNA drug highlights investor enthusiasm for approaches that offer complementary benefits, such as preserving muscle mass, signaling a new chapter in obesity treatment.

The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.

Selina Koch says Arrowhead's healthy-volunteer data showed up to 73% tau knockdown, a first for siRNA in people. But Biogen's intrathecal antisense showed more knockdown at higher doses without matching efficacy; the lowest dose worked best, raising whether excess tau knockdown is harmful; patient data are needed.

Facing industry-wide skepticism in 2010, Alnylam implemented a highly disciplined R&D strategy. They focused exclusively on targets that met strict criteria: liver expression (where delivery worked), human genetic validation (to de-risk biology), and an early biomarker. This strategic focus was key to their survival and success.

While current RNAi therapies are successful, they almost exclusively target liver cells (hepatocytes). The industry is only at the beginning of its journey. The real, massive opportunity lies in cracking the delivery challenge to target other cells, tissues, and organs with unmet medical needs.

Thalia's strategy isn't to compete with established players on single-target assets. Instead, it aims to create a new category with bispecific siRNAs that target multiple disease pathways simultaneously, combined with novel delivery systems to reach tissues beyond the liver.

Arrowhead's demonstration of over 80% tau knockdown in CSF signals that transferrin-mediated delivery is expanding beyond enzymes and antibodies into siRNA conjugates. Much like GalNAc revolutionized liver targeting, transferrin technology is maturing across multiple competitors to overcome blood-brain barrier penetration challenges.

"China Speed," once synonymous with rapid antibody development, now extends to RNA silencing technologies. A surge in homegrown RNAi companies and programs, with dozens unpartnered, indicates China's biotech ecosystem is rapidly diversifying into new, complex therapeutic modalities beyond its established strengths.

Next siRNA race is delivery to non-liver tissues | RiffOn